Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019)
Arbutus Biopharma (ABUS) posted quarterly Cash from Restructuring of -$66000.0 for Q4 2019, down 111.76% year-on-year from $561000.0 in Q4 2018, and up 52.17% on a QoQ basis from -$138000.0 in Q3 2019.
Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Cash from Restructuring for 2 consecutive years, with -$66000.0 the latest figure, recorded in Q4 2019.
- Quarterly Cash from Restructuring fell 111.76% year-over-year to -$66000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was -$983000.0 (down 159.04% YoY) and the FY2019 annual result came in at -$983000.0, down 173.85% from the prior year.
- Cash from Restructuring advanced to -$66000.0 in Q4 2019 per ABUS's latest filing, from -$138000.0 in the prior quarter.
- Over the last five years, Cash from Restructuring for ABUS reached as high as $1.0 million in Q1 2018 and fell as low as -$640000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -66,000.00 |
| Sep 30, 2019 | -138,000.00 |
| Jun 30, 2019 | -640,000.00 |
| Mar 31, 2019 | -139,000.00 |
| Dec 31, 2018 | 561,000.00 |
| Sep 30, 2018 | -320,000.00 |
| Jun 30, 2018 | 395,000.00 |
| Mar 31, 2018 | 1.03 Mn |